Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours

Br J Cancer. 2011 Mar 29;104(7):1067-70. doi: 10.1038/bjc.2011.76. Epub 2011 Mar 8.


Background: This study sought to determine the safety of single agent capecitabine, a pro-drug of 5FU, in patients with metastatic non-pancreatic neuroendocrine tumours (NETs).

Methods: Multicentre phase II, first-line study design. Oral capecitabine was administered on days 1-14 of 3-week cycles.

Results: Treatment was safe and well tolerated. Common toxicities were diarrhoea and fatigue.

Conclusion: The study provides evidence to support the use of capecitabine as a substitute for infusional 5FU in the management of NETs.

Publication types

  • Clinical Trial, Phase II
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antimetabolites, Antineoplastic / therapeutic use*
  • Capecitabine
  • Deoxycytidine / adverse effects
  • Deoxycytidine / analogs & derivatives*
  • Deoxycytidine / therapeutic use
  • Female
  • Fluorouracil / adverse effects
  • Fluorouracil / analogs & derivatives*
  • Fluorouracil / therapeutic use
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Metastasis / drug therapy
  • Neuroendocrine Tumors / drug therapy*


  • Antimetabolites, Antineoplastic
  • Deoxycytidine
  • Capecitabine
  • Fluorouracil